Founded in July 2020, GenAssist Ltd. (GenAssist) is a pioneering gene editing drug company. The operation entity of GenAssist is located in Suzhou, China, with two subsidiaries in Shanghai (China) and Boston (US). GenAssist has its own proprietary TAM base editing technology. Also, the Company has successfully established high throughput (~10b) unique AAV screening library and innovative gene editing tool platform. The company is dedicated to developing base editing drugs against life-threatening diseases. The first base editing product against Duchenne Muscular Dystrophy has entered clinical trial in August 2024 and will file IND at the end of 2024. GenAssist has closed three rounds of financing from famous VC funds, including Redhill capital, Sequoia China, Astrazeneca&CICC and Baidu VC.
Cooperation needs: B round financing (30M USD), DMD pipeline licensing out, AAV capsid licensing out.

Shanghai Huaota Biopharmaceutical Co., Ltd. (aka ‘Huaota’) was established in September 2013. Huaota is a subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd.
Driven by innovation and development, Huaota has built comprehensive and integrated platforms to develop novel biologics. The R&D platform at Huaota supports the identification and development of new monoclonal antibodies, bispecific antibodies, fusion proteins, ADC drugs, etc.
Independent research and development drive innovation. Huaota has a diverse product pipeline covering therapeutic areas such as tumors and autoimmune diseases. At present, there are over twenty projects under development. Many of them have obtained IND approval and multiple clinical trials are undertaken in the United States, New Zealand, and China. In 2019, Huaota was certified as High- and New-Technology Enterprise. By now, Huaota has applied for several domestic and international invention patents.
Huaota Biopharmaceutical is actively seeking domestic and international partners to collaborate and advance these projects that aim to provide high-quality, advanced biological drugs to the global market, meeting the demand for accessible and affordable biopharmaceuticals. The vision is to innovate and change the world through these efforts.

Zhejiang Yangli Pharmaceutical Technology Co., Ltd (Vybio) is a Chinese national high-tech enterprise and a technology-based SME focused on developing FIC innovative drugs with global IP. The company’s product portfolio is concentrated on oncology and chronic disease fields. Development pipeline includes drugs for refractory tumors, breast cancer, and chronic diseases, with platforms for precision therapy small-molecule drugs and SiRNA gene-based drugs. The company has developed eight first-in-class drugs, two of which have entered Phase II clinical trials. 

ImmVira is a clinical-stage biotechnology company focusing on developing HSV-1 based oncolytic virotherapy, with established end-to-end capabilities from drug discovery to CMC, inherently reducing modality related development risks.
Leveraging HSV-1 as well-validated oncolytic agent, ImmVira’s core product MVR-T3011 adopted evolved backbone design with enhanced efficacy and modernized IO payload PD-1 and IL12, targeting a wide range of solid tumors via intratumoral (IT), intravenous (IV) and intravesical (IP) injection. MVR-T3011 is undergoing 7 Phase I/II clinical trials in the US and China, with head and neck (IT) and bladder cancer (IP) as leading indications. 

Founded in 2010, Wuhan YZY Biopharma Co., Ltd. (02496.HK) is a global biotechnology leader in treating oncology and autoimmune diseases. Specializing in innovative bispecific antibodies (BsAb), the company leverages its proprietary platforms, YBODY®, Check-BODY, and Nano-YBODY™, to develop a diverse pipeline of preclinical and clinical products. Key therapies include M701 (EpCAM×CD3 BsAb) for malignant ascites, Y101 (PD-L1×TGFβ BsAb) for solid tumors, and Y332 (VEGF×TGFβ BsAb) also for solid tumors.
Notably, M701 (EpCAM×CD3), a CD3-recruiting BsAb developed based on the YBODY® platform, has entered Phase 3 clinical trials for malignant ascites and demonstrated favorable safety and efficacy in Phase 2 trials. Additionally, Phase 1b/2 trials for M701 in malignant pleural effusion are ongoing.
With a mission to safeguard global health, Wuhan YZY Biopharma continues to innovate and collaborate to meet urgent healthcare needs worldwide.